Скачать или смотреть ARO-RAGE: What’s Really Going On With Arrowhead’s Asthma Drug?

Why has Arrowhead been so quiet about its asthma drug, ARO-RAGE?

Arrowhead Pharmaceuticals’ investigational drug ARO-RAGE could be a breakthrough treatment for severe asthma—leveraging RNAi to target the inflammatory RAGE pathway.

Early trial data was strong. But as the clinical story progressed, key updates—like the High FeNO subgroup analysis—have yet to surface.

So what’s going on?

In this episode, we explore:

ARO-RAGE’s development and early clinical success.
What Phase 1/2 trial data tells us (and what it doesn’t).
The mysterious delay around High FeNO results.
Why Arrowhead may be holding back disclosures.
Which Big Pharma partners might be circling.

🔍 This is more than just a pipeline update—it's a strategic moment in Arrowhead's licensing playbook.

This content is for informational and educational purposes only. I am not a financial advisor, and this is not financial advice. Investing in biotechnology stocks is highly speculative and carries significant risk, including the potential loss of principal. Always do your own thorough research and consult with a qualified financial professional before making any investment decisions.